Raffaele Palmieri

26PUBLICATIONS
129CO-AUTHORS
NanomedicineMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursBiomechanics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Aug 17, 2026
Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.

|Jan 28, 2026
Incidence and Characteristics of Perianal Infections in CPX-351-Treated AML Patients.

Elisa Buzzatti, Cristina Mauro, Cristiano Tesei

|Dec 05, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Raffaele Palmieri, Fabio Guolo, Luana Fianchi

|Sep 10, 2025
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias.

Alessandra Zaza, Giuseppe Zardo, Cristina Banella

|Jun 26, 2025
Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy.

Elisa Buzzatti, Giovangiacinto Paterno, Raffaele Palmieri

|Feb 06, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Adriano Venditti, Raffaele Palmieri, Luca Maurillo

Pageof 5

Frequent Collaborators

17 joint publications

Adriano Venditti

13 joint publications

Francesco Buccisano

11 joint publications

Luca Maurillo

8 joint publications

Maria Teresa Voso